Evidence map›Paper›PMID 35260913›Full record

ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2022

A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors.

Jonathan Metts, Brittany Harrington, Emad Salman, Scott M Bradfield, Jennifer Flanary, Maua Mosha, Ernest Amankwah, Stacie Stapleton

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00876993 (A Phase I Study Of Irinotecan and Bevacizumab With Temozolomide in Children With Recurrent/Refractory Central Nervous System Tumors), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00876993 phase1completednot on this map

A Phase I Study Of Irinotecan and Bevacizumab With Temozolomide in Children With Recurrent/Refractory Central Nervous System Tumors

TypeinterventionalSponsorJohns Hopkins All Children's HospitalRan2008 to 2015Enrolled26ConditionsCentral Nervous System TumorsArmsBevacizumab, Irinotecan, Temozolomide
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Bevacizumab in Pediatric Neuro-Oncology.Current oncology (Toronto, Ont.) · 2025
    Review
  2. Review
  3. Review
  4. Targeting Angiogenic Factors for the Treatment of Medulloblastoma.Current treatment options in oncology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Jonathan MettsCancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, 501 6th Avenue South, St Petersburg, FL, 33701, USA. jmetts1@jhmi.edu.ORCID 0000-0003-1068-7857
Brittany HarringtonHospital Medicine, MyMichigan Health, Alma, MI, USA.
Emad SalmanGolisano Children's Hospital of Southwest Florida, Fort Myers, FL, USA.
Scott M BradfieldDivision of Pediatric Hematology/Oncology, Nemours Children's Health, Jacksonville, FL, USA.
Jennifer FlanaryData Coordinating Center for Pediatric Multicenter Studies, Institute for Clinical and Translational Research, Johns Hopkins All Children's Hospital, St Petersburg, FL, USA.
Maua MoshaData Coordinating Center for Pediatric Multicenter Studies, Institute for Clinical and Translational Research, Johns Hopkins All Children's Hospital, St Petersburg, FL, USA.
Ernest AmankwahData Coordinating Center for Pediatric Multicenter Studies, Institute for Clinical and Translational Research, Johns Hopkins All Children's Hospital, St Petersburg, FL, USA.
Stacie StapletonCancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, 501 6th Avenue South, St Petersburg, FL, 33701, USA.
Johns Hopkins University · USGolisano Children's Hospital of Southwest Florida · USMidMichigan Medical Center - Midland · USNemours Children's Health System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeChildren with relapsed/refractory central nervous system (CNS) tumors require novel combinations of therapies. Irinotecan and temozolomide (IT) is a frequently used therapy with an established toxicity profile. Bevacizumab is an anti-VEGF monoclonal antibody with demonstrated activity in CNS tumors. Therefore, the combination of these agents has therapeutic potential in CNS tumors. The objective of this study was to determine the maximum tolerated dose (MTD) of escalating dose IT combined with a fixed dose of bevacizumab (BIT) in children with relapsed/refractory CNS tumors.

methodsA phase I trial was performed in a 3 + 3 design. Therapy toxicities and radiologic responses to treatment were described.

resultsOne hundred eighty cycles of therapy were administered to 26 patients. The MTD of BIT was dose level 1, (bevacizumab 10 mg/kg on days 1 and 15, irinotecan 125 mg/m

conclusionAt the MTD, BIT therapy was well tolerated, and prolonged treatment courses of up to 24 cycles were feasible, with radiographic responses observed. Further evaluation is needed for efficacy in a phase II trial (NCT00876993, registered April 7, 2009, www. CLINICALTRIALS: gov ).

Indexed as

Central Nervous System NeoplasmsDacarbazineAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCamptothecinChildHumansIrinotecanTemozolomideBevacizumabCamptothecinDacarbazineIrinotecanTemozolomideBevacizumabBrain tumorIrinotecanPediatricPhase ITemozolomide

Identifiers

PMID35260913
OpenAlexW4220945815

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.